Investigation of the drug-drug interaction between α-lipoic acid and valproate via mitochondrial β-oxidation

Pharmaceutical Research

Volumn 25, Issue 11, 2008, Pages 2639-2649

  Phua, Lee Cheng ^a   New, Lee Sun ^a   Goh, Catherine W ^b   Neo, Aveline H ^b   Browne, Edward R ^b   Chan, Eric C Y ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Helios Building #03 01/02   (Singapore)

Author keywords

oxidation; Drug drug interaction; Lipoic acid; Mitochondrial; Valproate

Indexed keywords

THIOCTIC ACID; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PROTEIN BINDING; FATTY ACID OXIDATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CHROMATOGRAPHY, LIQUID; CITRATE (SI)-SYNTHASE; DRUG INTERACTIONS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; MITOCHONDRIA, LIVER; OXIDATION-REDUCTION; PROTEIN BINDING; RATS; THIOCTIC ACID; VALPROIC ACID;

EID: 53849142522     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9681-5     Document Type: Article

References (30)

1. L. Holmquista G. Stuchburya K. Berbauma S. Muscata S. Youngb K. Hagerc J. Engeld G. Münch 2007 Lipoic acid as a novel treatment for Alzheimer's disease and related dementias Pharmacol. Ther 113 154 164
2. A. R. Smith S. V. Shenvi M. Widlansky J. H. Suh T. M. Hagen 2004 Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress Curr. Med. Chem 11 1135 46
3. B. Frank S. Gupta 2005 A review of antioxidants and Alzheimer's disease Ann. Clin. Psychiatry 17 269 286
4. S. Sola M. Q. S. Mir F. A. Cheema N. Khan-Merchant R. G. Menon S. Parthasarath B. V. Khan 2005 Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study Circulation 111 343 348
5. J. L. Meyerhoff J. K. Lee B. W. Rittase A. Y. Tsang D. L. Yourick 2004 Lipoic acid pretreatment attenuates ferric chloride-induced seizures in the rat Brain Res 1016 139 144
6. D. Malińska K. Winiarska 2005 Lipoic acid: characteristics and therapeutic application Postepy. Hig. Med. Dosw 59 535 43
7. H. Schupke R. Hempel G. Peter R. Hermann K. Wessel J. Engel T. Kronbach 2001 New metabolic pathways of α-lipoic acid Drug. Metab. Dispos 29 855 862
8. J. Teichert R. Hermann P. Ruus R. Preiss 2003 Plasma kinetics, metabolism and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers J Clin Pharmacol 43 1257 1267
9. L. J. Willmore 2003 Divalproex and epilepsy Psychopharmacol Bull 37 43 53
10. V. Pucci E. Monteagudo F. Bonelli 2005 High sensitivity determination of valproic acid in mouse plasma using semi-automated sample preparation and liquid chromatography with tandem mass spectrometric detection Rapid. Commun. Mass Spectrom 19 3713 3718
11. M. F. Meek J. Broekroelofs J. P. Yska P. H. Egbers E. C. Boerma P. H. van der Voort 2004 Valproic acid intoxication: sense and non-sense of haemodialysis Neth. J. Med 62 333 6
12. S. Minucci P. G. Pelicci 2006 Histone deacetylase inhibitors and the promise of epigenetic (and more) treatment of cancer Nat. Rev. Cancer 6 38 51
13. G. Lehrman I. B. Hogue S. Palmer C. Jennings C. A. Spina A. Wiegand 2005 Depletion of latent HIV-1 infection in vivo: a proof-of-concept study Lancet 366 549 555
14. M. F. B. Silva L. IJlst P. Allers C. Jakobs M. Duran I. T. Almeida R. J. A. Wanders 2004 Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria Drug. Metab. Dispos 32 1304 1310
15. C. F. Lacy, L. L. Armstrong, M. P. Goldman, and L. L. Lance. Drug information handbook with international trade names index. Lexi-comp, Canada, 2007.
16. M. F. B. Silva J. P. N. Ruiter L. IJlst P. Allers H. J. T. Brinks C. Jakobs M. Duran I. T. Almeida R. J. A. Wanders 2001 Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites Anal. Biochem 290 60 67
17. W. D. Hooper M. E. Franklin P. Glue 1996 Effect of felbamate on valproic acid disposition in healthy volunteers: Inhibition of β-oxidation Epilepsia 37 91 97
18. Drugdex Evaluation (Felbamate), part of Thomson Micromedex Healthcare Series http://www.thomsonhc.com.libproxy1.nus.edu.sg (accessed 24/02/07).
19. G. E. Mawer B. J. Pleuvry 1995 Interactions involving new antiepileptic drugs Pharmacol. Ther 68 209 231
20. st Ed. Oxford University Press, New York, 1997.
21. P. A. Srere 1969 Citrate synthase Methods Enzymol 13 3 11
22. S. M. Bjorge T. A. Baillie 1991 Studies on the β-oxidation of valproic acid in rat liver mitochondrial preparations Drug. Metab. Dispos 19 823 829
23. K. B. Burns L. T. Gelbaum M. C. Sullards D. E. Bostwick S. W. May 2005 Iso-coenzyme A J. Biol. Chem 280 16550 16558
24. R. J. C. A. Steen A. C. Hogenboomb P. E. G. Leonardsb R. A. L. Peerbooma W. P. Cofino U. A. Th. Brinkmanb 1999 Ultra-trace-level determination of polar pesticides and their transformation products in surface and estuarine water samples using column liquid chromatography-electrospray tandem mass spectrometry J. Chromatogr. A 857 157 166
25. K. Breithaupt-Grögler G. Niebch E. Schneider K. Erb R. Hermann H. H. Blume B. S. Schug G. G. Belz 1999 Dose-proportionality of oral thioctic acid-coincidence of assessments via pooled plasma and individual data Eur. J. Pharm. Sci 8 57 65
26. S. S. Singh J. Mehta 2006 Measurement of drug-protein binding by immobilized human serum albumin-HPLC and comparison with ultrafiltration J. Chromatogr. B 834 108 116
27. I. Bekersky R. M. Fielding D. E. Dressler J. W. Lee D. N. Buell T. J. Walsh 2002 Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate Antimicrob. Agents Chemother 46 834 840
28. S. Taylor A. Harker 2006 Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids J. Pharm. Biomed. Anal 41 299 303
29. T. Rodgers M. Rowland 2007 Mechanistic approaches to volume of distribution predictions: understanding the processes Pharm. Res 24 918 933
30. R. G. Dickinson R. C. Harland A. M. Ilias R. M. Rodgers S. N. Kaufman R. K. Lynn N. Gerber 1979 Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, hepatic recirculation and choleretic effect J Pharmacol Exp Ther 211 583 595